Share This
Create Your Own Business Intelligence Website
 
Input the stock code or the company name     Search  

<01093.HK> - CSPC Pharmaceutical Group Limited

 
 
 Basic Datum
Company name Lot P/E P/B EPS DPS
CSPC PHARMA 2000 13.39 1.8706 0.5423 0.28
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 
 
 
 Company Rating
Date Broker Company name Rating Target
≫More
 
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
≫More
 
 Comment
2024-10-18　智通財經ＡＰＰ獲悉，中金發表報告稱，保持石藥集團利潤預計不變，當前股價對應２０２４/２５年市盈率１０/９倍，保持「跑贏行業」評級和目標價８．４港元不變，對應２０２４/２５年市盈率１４/１２倍。據悉，近日石藥集團控股子公司石藥創新制藥(新諾威，３００７６５．ＳＺ)公告發行股權及支付現金購買資產並募集配套資產的具體方案。
 
2024-11-01　ＭＳＣＩ ＥＳＧ評級是深受全球投資機構廣泛認可的ＥＳＧ評價體系之一，評級權威度、公信度高，評級結果被國內外投資者廣泛應用於投資決策中。石藥集團一直秉持可持續發展理念，致力於有幫推動ＥＳＧ各項實踐，本年度再度獲評Ａ級，體現了國際資本市場對石藥集團管理成果的認可。
 
2024-11-15　財聯社１１月１日電，石藥集團低開１３％後跌幅收窄，截至發稿跌１０％，成交近３億港元。該公司昨天公布公告，估計集團前三季度的公司擁有人應占淨盈利將同比消減約１６％。
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
HSI 01-13 09:30 18846.2 ▼ 218.14 ▼ 1.14%
CSPC PHARMA 05-08 10:26 6.68 ▲ 6.68 ▲ ∞%
≫More
 
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.